Last checked at 4 Jan 2023 13:33
SkinBioTherapeutics plc
Results of General Meeting
4 January 2023 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's General Meeting, held today 4 January 2023, all resolutions were duly passed.
Details of the proxy votes received on each resolution by the Company's Registrar are set out below:
Resolution | For & Discretionary | Against | Withheld | ||||
|
| Number of votes | % | Number of votes | % | Number of votes | % |
01 | Special resolution to the dis-application of the pre-emption provisions set out in section 561(1) of the Companies Act 2006 in relation to the allotment of equity securities up to a maximum nominal amount of £218,750 in connection with the Placing and the Retail Offer | 33,676,715 | 99.40% | 202,201 | 0.60% | 741 | 0.00% |
Accordingly, the Company will raise a total of £2.62 million (before expenses) via a Placing and Retail Offer through the issue and allotment of 16,358,618 new Ordinary Shares. An application has been made for the new Ordinary Shares to be admitted to trading on AIM, which is expected to take place at 0800 on 5 January 2023.
Following admission of the New Ordinary Shares, the Company's issued share capital will comprise 173,138,854 Ordinary Shares, of which none are held in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 16 December 2022.
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Stuart J. Ashman, CEOManprit Randhawa, CFO | Tel: +44 (0) 191 495 7325 |
Cenkos Securities Plc (Nominated Adviser & Broker)Giles Balleny, Max Gould (Corporate Finance)Dale Bellis, Tamar Cranford-Smith (Sales) | Tel: +44 (0) 20 7397 8900 |
Instinctif Partners (financial press) Melanie Toyne-Sewell / Tim Field | Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics @instinctif.com |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com.